

## 2019-2020

### American Heart Association

#### Support from Pharmaceutical and Biotech Companies, Device Manufacturers and Health Insurance Providers

We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association's finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau's Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations and estates as well as investment earnings and revenue from the sale of educational materials.

Financial support from corporations helps the association's programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association's corporate relations policies, and regional and national corporate relationships are approved by a committee of national volunteers and executive staff.

Total corporate support is comprised of unrestricted gifts and special event and program sponsorships, and includes support committed to the American Heart Association at the national, regional and local levels. Corporate Support represents approximately 23.8 percent of the AHA's \$795 million total revenue.

Support that the American Heart Association receives from pharmaceutical and biotech companies, device manufacturers and health insurance providers is included within total corporate support and represents approximately 5.0 percent of the association's total revenue. The majority of funding from these sources occurs at the national level.

The revenue figures below include the total amount of funds committed to the American Heart Association during fiscal year 2019-2020, noting that, in some cases, the funds will be received in future years. The chart provides funds committed from pharmaceutical and biotech companies, device manufacturers and health insurance providers in proportion to all sources of revenue.



Following is a schedule of corporate support provided to the American Heart Association from pharmaceutical and biotech companies, medical device manufacturers and health insurance providers during fiscal year 2019-2020. The schedule reflects cash received during fiscal year 2019-2020 and revenue committed to the American Heart Association that will be received in future years.

2019-2020 Corporate Support Received from Pharmaceutical and Biotech Companies, Medical Device Manufacturers and Health Insurance Providers		
Corporation	Total Cash Received During 2019-2020 on Prior and Current Year Commitments (1)	2019-2020 Commitments Receivable in the Future
3M	\$ 100,000	\$ -
Abbott	-	124,998
Amarin	775,000	-
AmerisourceBergen	200,000	-
Amgen	3,275,000	1,950,000
Alnylam Pharmaceuticals	250,000	-
Anthem	1,639,518	4,326,040
AstraZeneca	6,482,500	105,000
Bard/BD	200,000	60,000
Bayer Healthcare	1,808,333	833,333
Biogen	22,500	-
Blue Cross Blue Shield of NC	500,000	-
Blue Shield of California	250,000	-
BMS/Pfizer	635,819	-
BI/Lilly	2,002,269	3,000,000
Boehringer Ingelheim Pharmaceuticals	1,822,450	-
Cerenovus	25,000	-
Chiesi	15,000	-
CSL Behring	30,000	-
Cytokinetics	80,000	-
Data Sciences International	1,000	-
Delta Dental	31,250	483,750
Denka Seiken USA	20,000	-
Edwards Lifesciences LLC	3,800,000	6,500,000
Esperion Therapeutics, Inc.	180,000	-
FirstKind Ltd	24,965	-
Florida Blue	-	300,000
Genentech	410,500	-
Gore Medical	30,000	-
Humana	25,000	-
Independence Blue Cross	125,000	-
Jabil	75,000	-
Janssen	457,500	-
Janssen Biotech	283,335	120,000
Johnson & Johnson	383,137	-
Kaiser Permanente	525,000	-
Laerdal Medical Corporation	600,000	1,350,000
Livongo Health	25,000	-
Medtronic/Covidien/EV3	1,257,150	912,500
Merck	105,000	-
MyoKardia	940,000	2,390,000
Nephron Pharmaceuticals	75,000	-
Novartis Pharmaceuticals	3,082,187	-
NovoNordisk	1,635,000	-
Parker Hannifin	62,500	-
Pfizer	388,325	-
Philips Healthcare	125,000	-
Portola Pharmaceuticals, Inc.	1,467,724	2,600,000
Quest Diagnostics	17,500	-
Reckitt Benckiser	125,000	-
Regeneron	50,000	-
Sanofi	1,775,000	-
Schiller Americas, Inc.	37,500	512,500
Siemens USA	200,000	-
Stryker Neurovascular	15,000	-
Syntheon	20,000	-
The Medicines Company	360,000	-
Transamerica	500,000	-
UnitedHealthcare	75,000	-
Verily (Google Life Science)	4,717,409	-
Verve Therapeutics	5,000	-
Western Health Advantage	115,000	-
<b>Totals</b>	<b>\$ 44,260,371</b>	<b>\$ 25,568,121</b>

NOTE: (1) Reflects all cash received from corporate contributions to National Center and ten highest corporate contributions to each Region. Revenue related to the cash receipts was recorded within AHA's financial statements over the periods from fiscal year 2014-2015 through fiscal year 2019-2020.